Combination Therapy and Long-Term Safety Quiz

Which molecule represents 44% market share in the 1st year with 2,156 units and grew by 487%?

Which molecule is represented by 1,621 units, lost market share by 19%, and declined by -35% YOY 2022?

Which molecule is represented by 826 units, gained 10% market share, and grew by 1,696%?

Which molecule represents 67% market share and is growing vs the decline of Bosentan?

Which product significantly reduced the risk of the first morbidity and mortality event by 45%?

Which product offers an average 5.9 years of survival in combination therapy?

Which product had patients on 10mg with a greater chance to improve FC Status by 74%?

Which product significantly increased the 6-minute walk distance by 22 meters?

Which product significantly reduced death due to PAH or hospitalization by 45%?

Which product had patients receiving the 10mg combination therapy with a reduction in the risk of being hospitalized for PAH of 37.4%?